These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19340881)

  • 1. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Inflamm Bowel Dis; 2009 Sep; 15(9):1295-301. PubMed ID: 19340881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study.
    Crombé V; Salleron J; Savoye G; Dupas JL; Vernier-Massouille G; Lerebours E; Cortot A; Merle V; Vasseur F; Turck D; Gower-Rousseau C; Lémann M; Colombel JF; Duhamel A
    Inflamm Bowel Dis; 2011 Oct; 17(10):2144-52. PubMed ID: 21287665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic monitoring of infliximab therapy in Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila PE; Sipponen T; Färkkilä MA
    Inflamm Bowel Dis; 2011 Apr; 17(4):947-53. PubMed ID: 20860048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early serum infliximab trough level and mucosal healing could be predictors for one-year outcome after initiating therapy in Crohn's disease.
    Tang J; Yang Q; Huang Z; Guo H; Chao K; Hu P; Gao X
    Scand J Gastroenterol; 2020 Sep; 55(9):1035-1040. PubMed ID: 32819192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
    Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
    Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study.
    Biancone L; Petruzziello C; Orlando A; Kohn A; Ardizzone S; Daperno M; Angelucci E; Castiglione F; D'Incà R; Zorzi F; Papi C; Meucci G; Riegler G; Sica G; Rizzello F; Mocciaro F; Onali S; Calabrese E; Cottone M; Pallone F
    Inflamm Bowel Dis; 2011 Mar; 17(3):758-66. PubMed ID: 20684009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
    Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
    Laharie D; Filippi J; Roblin X; Nancey S; Chevaux JB; Hébuterne X; Flourié B; Capdepont M; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 May; 37(10):998-1004. PubMed ID: 23521659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease.
    Grover Z; Burgess C; Muir R; Reilly C; Lewindon PJ
    J Crohns Colitis; 2016 Oct; 10(10):1159-64. PubMed ID: 26980840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. factors influencing mucosal healing in Crohn's disease during infliximab treatment.
    Tursi A; Elisei W; Giorgetti GM; Penna A; Picchio M; Brandimarte G
    Hepatogastroenterology; 2013; 60(125):1041-6. PubMed ID: 23803367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term risk of infection in patients with Crohn's disease on anti-TNF treatment: A prospective single-center cohort study in China.
    Li Y; Shu HJ; Lu H; Yang H; Li J; Tan B; Qian JM
    J Dig Dis; 2017 Jul; 18(7):388-394. PubMed ID: 28644565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.
    Ananthakrishnan AN; Korzenik JR; Hur C
    Inflamm Bowel Dis; 2013 Jan; 19(1):37-44. PubMed ID: 22416019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.